Polymeric Nanoparticles of Aromatase Inhibitors: A Comprehensive Review.
Breast cancer
aromatase
aromatase inhibitors
estrogen
nano drug delivery
nanoparticles
Journal
Current pharmaceutical design
ISSN: 1873-4286
Titre abrégé: Curr Pharm Des
Pays: United Arab Emirates
ID NLM: 9602487
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
04
2020
accepted:
18
08
2020
pubmed:
30
9
2020
medline:
27
4
2021
entrez:
29
9
2020
Statut:
ppublish
Résumé
Being the second most frequent cancer, breast cancer is emerging worldwide with an alarming rate, specifically in post-menopausal women. Targeted drug delivery has been in the focus for the successful treatment of breast cancer by enhancing the drug delivery efficiency and reducing the systemic toxicity of drugs. Also, it eliminates the drawbacks associated with conventional chemotherapy, including neuropathy, memory loss, cardiotoxicity and low RBCs count. This review elaborates the polymeric nanoparticles based formulation approaches for selective and sustained delivery for effective cure of breast cancer. However, breast cancer, a life-threatening disease, is mostly caused because of estrogen, thus aromatase inhibitors and estrogen synthesis inhibitors could prevent chances of breast cancer. The disease is associated with drug resistance and some side effects, which could be easily eliminated by using novel therapeutic approaches. Aromatase inhibitors, when entrapped in nanoparticles, have shown sustained drug release, advocating themselves to be beneficial for the treatment of breast cancer.
Identifiants
pubmed: 32990532
pii: CPD-EPUB-110316
doi: 10.2174/1381612826666200929123715
doi:
Substances chimiques
Aromatase Inhibitors
0
Estrogens
0
Aromatase
EC 1.14.14.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
855-865Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.